These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37840379)

  • 1. Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas.
    Katsuragawa-Taminishi Y; Mizutani S; Kawaji-Kanayama Y; Onishi A; Okamoto H; Isa R; Mizuhara K; Muramatsu A; Fujino T; Tsukamoto T; Shimura Y; Taniwaki M; Miyagawa-Hayashino A; Konishi E; Kuroda J
    Cancer Sci; 2023 Dec; 114(12):4691-4705. PubMed ID: 37840379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TAS0612, a Novel RSK, AKT, and S6K Inhibitor, Exhibits Antitumor Effects in Preclinical Tumor Models.
    Ichikawa K; Ito S; Kato E; Abe N; Machida T; Iwasaki J; Tanaka G; Araki H; Wakayama K; Jona H; Sugimoto T; Miyadera K; Ohkubo S
    Mol Cancer Ther; 2024 Feb; 23(2):174-186. PubMed ID: 37906695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.
    Maegawa S; Chinen Y; Shimura Y; Tanba K; Takimoto T; Mizuno Y; Matsumura-Kimoto Y; Kuwahara-Ota S; Tsukamoto T; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
    Exp Hematol; 2018 Mar; 59():72-81.e2. PubMed ID: 29287939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma.
    Isa R; Horinaka M; Tsukamoto T; Mizuhara K; Fujibayashi Y; Taminishi-Katsuragawa Y; Okamoto H; Yasuda S; Kawaji-Kanayama Y; Matsumura-Kimoto Y; Mizutani S; Shimura Y; Taniwaki M; Sakai T; Kuroda J
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphoinositide protein kinase PDPK1 is a crucial cell signaling mediator in multiple myeloma.
    Chinen Y; Kuroda J; Shimura Y; Nagoshi H; Kiyota M; Yamamoto-Sugitani M; Mizutani S; Sakamoto N; Ri M; Kawata E; Kobayashi T; Matsumoto Y; Horiike S; Iida S; Taniwaki M
    Cancer Res; 2014 Dec; 74(24):7418-29. PubMed ID: 25269480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
    Uddin S; Hussain AR; Siraj AK; Manogaran PS; Al-Jomah NA; Moorji A; Atizado V; Al-Dayel F; Belgaumi A; El-Solh H; Ezzat A; Bavi P; Al-Kuraya KS
    Blood; 2006 Dec; 108(13):4178-86. PubMed ID: 16946303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.
    Mazan-Mamczarz K; Peroutka RJ; Steinhardt JJ; Gidoni M; Zhang Y; Lehrmann E; Landon AL; Dai B; Houng S; Muniandy PA; Efroni S; Becker KG; Gartenhaus RB
    Cell Commun Signal; 2015 Mar; 13():15. PubMed ID: 25849580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
    Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.
    Majchrzak A; Witkowska M; Smolewski P
    Molecules; 2014 Sep; 19(9):14304-15. PubMed ID: 25215588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma.
    Pene F; Claessens YE; Muller O; Viguié F; Mayeux P; Dreyfus F; Lacombe C; Bouscary D
    Oncogene; 2002 Sep; 21(43):6587-97. PubMed ID: 12242656
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas.
    Islam S; Qi W; Morales C; Cooke L; Spier C; Weterings E; Mahadevan D
    Mol Cancer Ther; 2017 Oct; 16(10):2083-2093. PubMed ID: 28615297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.
    Wanner K; Hipp S; Oelsner M; Ringshausen I; Bogner C; Peschel C; Decker T
    Br J Haematol; 2006 Sep; 134(5):475-84. PubMed ID: 16856892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.
    Ezell SA; Wang S; Bihani T; Lai Z; Grosskurth SE; Tepsuporn S; Davies BR; Huszar D; Byth KF
    Oncotarget; 2016 Feb; 7(8):9163-74. PubMed ID: 26824321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo role of the phosphate groove of PDK1 defined by knockin mutation.
    Collins BJ; Deak M; Murray-Tait V; Storey KG; Alessi DR
    J Cell Sci; 2005 Nov; 118(Pt 21):5023-34. PubMed ID: 16219676
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
    Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
    Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
    Strömberg T; Feng X; Delforoush M; Berglund M; Lin Y; Axelson M; Larsson O; Georgii-Hemming P; Lennartsson J; Enblad G
    Med Oncol; 2015 Jul; 32(7):188. PubMed ID: 26021470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.